Helius Medical Technologies Announces Reimbursement Determination For PoNs Mouthpiece Set At $2,963.30 On Lump Sum Payment To Be Challenged By Co; Disagrees With CMS' Methods, Pricing & Deferral For Determining Payment Rates For PoNs Mouthpiece & Pons Controller
Portfolio Pulse from Benzinga Newsdesk
Helius Medical Technologies is challenging the CMS reimbursement determination for its PoNS Mouthpiece set at $2,963.30. The company disagrees with CMS' methods and pricing. The reimbursement for the PoNS Controller has been deferred to the next cycle.
October 14, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Helius Medical Technologies is disputing the CMS reimbursement rate for its PoNS Mouthpiece, set at $2,963.30, and is unhappy with the methods and pricing used. The decision on the PoNS Controller has been deferred.
The challenge to the CMS reimbursement rate indicates potential financial and operational impacts for Helius Medical Technologies. The disagreement with CMS could lead to uncertainty and affect investor sentiment negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100